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Edited by Varda RotterAbstract The tumor suppressor p53 can translocate into mito-
chondria and activate apoptosis. Here we studied whether p53
mitochondrial translocation and subsequent apoptosis were af-
fected by blocking mitochondrial permeability transition pore
using cyclosporine A (CsA) and bongkrekic acid (BA) in skin
epidermal JB6 cells and skin tissues. Our results demonstrated
that CsA and BA blocked TPA-induced p53 translocation, lead-
ing to protection against the loss of mitochondrial membrane po-
tential and Complex I activity, and eventually suppression of
apoptosis. Thus, our results suggest that mitochondrial perme-
ability transition is required for p53 mitochondrial translocation.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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In the tumor promoter 12-O-tetradecanoylphorbol 13-ace-
tate (TPA)-treated mouse skin epidermal JB6 cells and skin tis-
sues [1–4], we demonstrated several interesting observations:
(1) the tumor suppressor p53 was activated after TPA treat-
ment; (2) a fraction of p53 translocated into mitochondria,
and the increase in mitochondrial p53 level was much greater
than that in the nucleus; (3) p53 translocation to mitochondria
preceded its nuclear translocation; (4) mitochondrial p53 tar-
geted a primary antioxidant defense enzyme, manganese super-
oxide dismutase (MnSOD), leading to suppression of its
superoxide scavenging activity; and (5) mitochondrial p53
translocation and generation of reactive oxygen species
(ROS) were critical for p53 nuclear translocation. These results
suggest that p53 mitochondrial translocation might be an early
event and a critical step during p53-initiated apoptosis.
The tumor suppressor p53, upon activation by DNA-dam-
aging and oxidative stress-generating agents, can translocate
into mitochondria [5–8]. The proapoptotic activity of mito-
chondrial p53 seems to be synergized with that of the tran-
scription-dependent activity of p53, which eventually leads to
opening of mitochondrial permeability transition pore
(mPTP), cytochrome c release, and caspase activation [9–11].
In this report, we extended our previous studies on p53 trans-
location during early stage of the skin carcinogenesis to probe
how mitochondrion itself aﬀects p53 translocation. Since mito-*Corresponding author. Fax: +1 318 675 7857.
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and apoptosis, we address the question how mitochondrial
permeability transition aﬀects p53 translocation using cyclo-
sporine A and bongkrekic acid, to block mitochondrial transi-
tory pore.2. Materials and methods
2.1. Cell line, reagents, and TPA treatment
JB6 P+ (CL 41, promotable by 12-O-tetradecanoylphorbol 13-ace-
tate [TPA] treatment) was established and maintained as previously de-
scribed [12]. The cells were grown in EMEM medium supplemented
with 4% fetal bovine serum, 2 mM of L-glutamine, 50 lg/ml penicillin
and 50 lg/ml streptomycin. Ten millimolar cyclosporine A (CsA) and
5 mM bongkrekic acid (both were purchased from Sigma, St. Louis,
MO) stock solutions were prepared in phosphate buﬀered saline
(PBS, pH 7.4). 12-O-tetradecanoylphorbol-13-acetate (TPA, pur-
chased from Sigma) was prepared as 1 mM stock solution in dimethyl
sulfoxide (DMSO). It was diluted in culture medium to a ﬁnal concen-
tration of 100 nM for treatment of cells. 0.01% DMSO diluted in med-
ium was used as vehicle control.
2.2. Mice and treatment
DBA2/J mice were purchased from Jackson Laboratory (Indianap-
olis, IN) and maintained at Louisiana State University Health Sciences
Center-Shreveport animal facility. Twelve 6–8-week-old female mice
were divided into four groups (Vehicle control, TPA, CsA, CsA/
TPA) with three mice in each group. Mice were shaved as previously
described [1]. In Vehicle control group, mice were topically applied
with 200 ll DMSO; in the rest three groups, mice were topically ap-
plied with 100 nmol 7,12-dimethylbenz(a)-anthracene (DMBA, pur-
chased from Sigma) for 2 weeks, followed by 4 lg TPA for 6 h (TPA
group), or 200 nmol CsA for 1 h (CsA group), or 200 nmol CsA for
1 h followed by 4 lg TPA for 6 h (CsA/TPA group). Mice were then
euthanized and skin tissues were collected as previously described [1].
2.3. Detection of mitochondrial membrane potential
Five thousand JB6 cells were seeded in 96-well plates with 150 ll
medium. Twenty-four hours after plating, the cells were treated with
1, 5 or 10 lM CsA for 30 min. The medium was replaced with fresh
medium containing 100 nM TPA for 1 h. After washing with cold
PBS, cells were incubated in culture medium containing 2 lg/ml of
5,5 0,6,6 0-tetrachloro-1,1 0,3,3 0-tetraethylbenzimidazol-carbocyanine io-
dide (JC-1, Molecular Probes, Eugene, Oregon) for 30 min. The dye
was then removed and cells were washed with PBS. Fluorescence inten-
sity was measured immediately by ﬂuorescence spectrometry (Spectra
MAX GEMINI, Molecular Devices, Sunnyvale, CA). For JC-1 green,
Ex = 485, Em = 525; for JC-1 red, Ex = 535, Em = 590.
2.4. Fluorescent staining of p53 immunoreactive protein
Ten thousand JB6 cells were seeded in eight-well Lab-Tek Chamber
Slides w/Cover (Nalge Nunc International, Naperville, IL) in 400 ll
medium per well and incubated overnight. Twenty-four hours after
plating, cells were incubated with 200 nM of MitoTracker Red CMX-blished by Elsevier B.V. All rights reserved.
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dye was removed, and cells were treated with 5 or 10 lM CsA for
30 min. Medium was replaced with either fresh medium or medium
containing TPA (100 nM) and incubated for 10 min, when TPA in-
duced p53 mitochondrial translocation [3]. Cell ﬁxation, staining,
and observation of ﬂuorescence were performed as described previ-
ously [3].
2.5. Isolation of mitochondrial fraction from JB6 cells and skin epidermal
tissues
JB6 cells were seeded into p100 plates (5 · 105 each plate) and incu-
bated overnight. After treatment with CsA for 30 min, medium was re-
moved and fresh medium containing vehicle (0.01% DMSO) or TPA
(100 nM) was added for 24 h. Cells were suspended in 2 ml mitochon-
dria isolation buﬀer (0.225 M mannitol, 0.075 M sucrose, 1 mM
EGTA, pH adjusted to 7.4 with 0.5 M Tris) in a 10-ml Wheaton
homogenizer tube and carefully homogenized for 30 strokes on ice.
The cell debris was removed by centrifugation at 576 · g (2200 rpm)
for 5 min in a Sorval SS34 rotor. The supernatant was ﬁltered through
a nylon screen cloth (Small Parts Inc., Miami Lakes, FL) and centri-
fuged at 9000 · g (8700 rpm) for 10 min. The pellet was washed by
adding 0.5 ml of mitochondria isolation buﬀer and centrifuging at
9000 · g for 5 min. This washing step was repeated once. The mito-
chondrial pellet was resuspended in various buﬀers depending on each
experimental design. Western blot analysis demonstrated that there
was trace mitochondrial protein SDHB in the supernatant fraction
and trace cytoplasmic contamination when GAPDH was used as a
marker, suggesting the isolated mitochondria were considerably pure.
Mouse skin tissues were stripped as previously described [1]. The
resulting cell suspension was used to isolate mitochondrial fraction fol-
lowing the procedures described above.
2.6. Preparation of whole cell lysate
JB6 cells were seeded and treated as described in the mitochondrial
isolation section. Cells were scraped from the plate into PBS, followed
by centrifugation. The pellet was resuspended in 100 ll of homogeniza-
tion buﬀer [20 mM HEPES (pH 7.0), 5 mM EGTA, 10 mM 2-mercap-
toethanol, 1 mM PMSF, 1 lg/ml leupeptin, 1 lg/ml aprotinin, and
1 lg/ml pepstatin]. Cells were then sonicated (using a Fisher 550 soni-
cator) for 10 s on ice at 40% scale. The lysate was centrifuged (50 · g or
600 rpm for 5 min) to remove cell debris; the resulting supernatant was
designated as whole cell lysate and kept at 80 C.2.7. Mitochondrial Complex I activity assays
Complex I speciﬁc activities were measured as described by Birch-
Machin et al. [13] with slight modiﬁcations [14]. Mitochondrial sam-
ples isolated from JB6 cells (protein concentration close to 1 lg/ll)
were subjected to three fast freeze–thaw cycles in hypotonic buﬀer be-
fore assay. The assay mixtures, which contained 25 mM potassium
phosphate buﬀer (pH 7.2), 5 mM MgCl2, 2 mM KCN, 2.5 mg/ml bo-
vine serum albumin (fraction V), 0.13 mM NADH, 65 mM coenzyme
Q1, and 2 mg/ml antimycin A, were incubated at 30 C for 1 min.
Mitochondria were added to initiate the reaction, and the initial rate
of NADH oxidation was monitored at 340 nm for 1 min (DA1). The
reaction was inhibited by 2 mg/ml of rotenone and the rate of NADH
oxidation was monitored for 1 min (DAr). The complex activity was
calculated according to the following formula: (DA1  DAr)/e/mg pro-
tein, e = 6.81 mM1 cm1. The relative levels (percentage of control) of
Complex I activity from three separate measurements were plotted to
present.2.8. Nucleosome fragmentation assay
JB6 cells were homogenized following the manufacturers instruc-
tions and the resulting supernatant was used to detect DNA fragmen-
tation by cell death detection ELISA (Roche, Indianapolis, IN).2.9. Western blot analysis
For detection of the protein levels of p53 in mitochondria, 20 lg of
mitochondrial fraction was separated on 10% SDS–PAGE gels and
transferred to a nitrocellulose membrane. For detection of cleaved
caspase-3, 20 lg of whole cell lysate (from JB6 cells) was applied to
10% SDS–PAGE gels. Membrane blocking and probing with anti-
bodies were performed as described previously [3]. The anti-cleavedcaspase-3 was purchased from Cell Signaling (Beverly, MA); anti-
GAPDH antibody from Trevigen (Gaithersburg, MD); and anti-
SDHB (Succinate dehydrogenase subunit B) antibody was purchased
from Santa Cruz (Santa Cruz, CA). For statistical analysis, the cor-
responding bands were scanned, and the densities were semiquantita-
tively assessed using VersaDoc Imaging System equipped with
QuantityOne software (Bio-Rad, Hercules, CA). For each set of data,
the experiments were repeated three times and representative images
were shown.
2.10. Statistical analysis
Statistical analysis was performed using one-way ANOVA followed
by Newman–Keuls post-test. Data are reported as means ± standard
error (S.E.M.). P < 0.05 was adjudged as signiﬁcant diﬀerence.3. Results
3.1. Blocking mitochondrial permeability transition pore
(mPTP) by cyclosporin A and bongkrekic acid suppressed
TPA-induced p53 mitochondrial translocation in JB6 cells
Previous studies demonstrated that TPA induced rapid
translocation of p53 into mitochondria. The increase in
mitochondrial p53 was observed as early as 10 min after
TPA treatment. Higher levels of mitochondrial p53 were ob-
served at 1 h and 24 h following TPA treatment [3]. Consis-
tent with that, immunoﬂuorescence staining of p53 protein
in skin epidermal JB6 cells (Fig. 1a) shows that following
TPA treatment, p53 (green ﬂuorescence) was increased in
mitochondria (10 min post TPA treatment), which was
evidenced by its co-localization with the mitochondrial mar-
ker MitoTracker (red ﬂuorescence). To investigate the role
of mPTP in p53 translocation, a mPTP blocker, cyclospor-
ine A (CsA) was used to treat JB6 cells prior to TPA treat-
ment. Neither 5 lM nor 10 lM concentration of CsA
increased p53 levels in mitochondria; whereas both concen-
trations suppressed TPA-induced p53 translocation. The ef-
fect of CsA on p53 translocation was further studied using
isolated mitochondrial fractions from JB6 cells. Fig. 1b
shows that there was an over 2-fold increase in mitochon-
drial p53 levels upon TPA treatment for 24 h (when mito-
chondrial p53 reaches a higher level based on a previous
study [3]). Not only 5 lM CsA, but also a lower concentra-
tion (1 lM) of CsA suppressed mitochondrial translocation
of p53. Another mPTP blocker, bongkrekic acid, was also
used. Similar to CsA, pretreatment with bongkrekic acid
(5 lM) suppressed TPA-induced p53 mitochondrial translo-
cation (Fig. 1b).
3.2. Cyclosporin A prevented mitochondrial dysfunction and
apoptosis associated with p53 translocation in JB6 cells
The following question is whether inhibition of p53 mito-
chondrial translocation by mPTP blockers can prevent mito-
chondrial dysfunction. Mitochondrial membrane potential
and Complex I activity were chosen as the markers for
mitochondrial function and cyclosporine A was used. Mito-
chondrial membrane potential can be monitored using JC-1.
JC-1 is a ratiometric dye that forms aggregates in a membrane
potential-dependent fashion. The ratio of aggregates (ﬂuores-
cence intensities at 590 nm [red]) and monomers (ﬂuorescence
intensities at 525 nm [green]) reﬂects the level of mitochondrial
membrane polarization. Following p53 translocation into
mitochondria after by TPA treatment, decreased mitochon-
drial membrane potential was observed, as shown in Fig. 2a.
Fig. 1. Blocking mitochondrial permeability transition pore inhibited TPA induced-p53 translocation into mitochondria. (a) Immunoﬂuorescence
staining of p53 in mitochondria. JB6 cells were grown in 8-well chamber slides. CsA was pretreated for 30 min. Green, p53 staining; red, MitoTracker
Red as the mitochondrial marker. (b) Western blot analysis and quantiﬁcation of p53 in mitochondria. SDHB served as a loading control. Three
independent experiments have been performed to determine the means and standard errors, one representative result was shown. CsA, cyclosporine
A; BA, bongkrekic acid. Both were pretreated for 30 min. Vehicle, 0.01% DMSO. *, P < 0.05 compared with control; #, P < 0.05 compared with
TPA treatment.
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TPA-induced decrease (by 37%) in membrane potential at
1 h time point. CsA alone at all three concentrations did not
aﬀect membrane potential signiﬁcantly. Similar results were
also observed at 24 h after TPA treatment (data not shown).
Next, mitochondrial Complex I activity was studied. Consis-
tent with the mitochondrial membrane potential study, TPA
treatment impaired Complex I activity (decreased by 20%).
However, this eﬀect was abolished when cells were pretreated
with 5 lM CsA (Fig. 2b). CsA alone showed almost no eﬀect
on Complex I activity.
It has been shown that direct target p53 to mitochondria can
cause cell death [15]. Consistent with that, increased levels of
cleaved caspase-3 were observed at 24 h after TPA treatment
(Fig. 2c). This increase was reduced when CsA (5 lM) was pre-
treated. Finally, apoptotic cell death was detected in TPA-trea-ted samples by a nucleosome fragmentation assay (Fig. 2d). In
summary, TPA-induced mitochondrial translocation of p53
was followed by impairment of mitochondrial functions, acti-
vation of caspase 3, and increase in nuclear DNA fragmenta-
tion. All of these events were signiﬁcantly reduced by CsA
pretreatment.
3.3. Cyclosporin A reduced the mitochondrial level p53 in skin
epidermal tissues
To examine if the above observations in skin keratinocytes
also occur during mouse skin carcinogenesis, mouse skin was
treated with 100 nmol DMBA for 2 weeks, then with 200 nmol
CsA for 1 h followed by a single application of 4 lg TPA for
6 h. DMBA/TPA treatment has been shown to induce apopto-
sis in addition to cell mitosis in skin epidermal tissues [1,2,4].
TPA treatment for 6 h was selected because previous studies
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Fig. 2. Cyclosporin A suppressed p53 translocation-associated mitochondrial dysfunction and apoptosis in JB6 cells. Cells were grown in p100
plates. Cells were treated when they reached 70% conﬂuence. CsA was pretreated for 30 min. Three independent experiments have been performed to
determine the means and standard errors, one representative result was shown. Control, 0.01% DMSO. *, P < 0.05 compared with control; #,
P < 0.05 compared with TPA treatment. (a) Monitoring mitochondrial membrane potential using JC-1 staining. The ratio of aggregates (ﬂuorescence
intensities at 590 nm) and monomer (ﬂuorescence intensities at 525 nm) was plotted as an indicator of mitochondrial membrane polarization. (b)
Measurement of mitochondrial Complex I activity. (c) Western blot analysis and quantiﬁcation of cleaved caspase-3. GAPDH served as a loading
control. (d) Quantitation of DNA fragmentation using cell death ELISA assay.
1322 J. Liu et al. / FEBS Letters 582 (2008) 1319–1324demonstrated that p53 mitochondrial translocation appears at
its peak at this time point [1]. There were three mice in each
group and the Western blot results were semiquantitatively
analyzed as the following: the density of each p53 band was di-
vided by the density of the corresponding SDHB band; the
p53/SDHB ratios were aligned in order in each group and
the second ratio (group comparison) was calculated one by
one accordingly.
As shown in Fig. 3, there was an approximately 3-fold in-
crease in p53 protein levels in the mitochondria. CsA alonedid not alter p53 levels signiﬁcantly, but it suppressed TPA-in-
duced mitochondrial p53 translocation.4. Discussion
Our previous studies have demonstrated that during early
skin carcinogenesis, not only cell proliferation is profound,
but also apoptotic cell death is increased [1]. Not surprisingly,
the tumor suppressor p53 was activated as indicated by in-
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Fig. 3. Cyclosporin A suppressed p53 mitochondrial tranlocation in
mouse skin epidermal tissues. Following the skin carcinogenesis
protocol, mice were treated with 100 nmol DMBA for 2 weeks. CsA
(200 nmol) was then applied for 1 h followed by a single application of
4 lg TPA for 6 h. The skin epidermal tissues were collected and
mitochondrial fraction was prepared for Western blot analysis.
Control: vehicle (DMSO). *, P < 0.05 compared with control; #,
P < 0.05 compared with TPA treatment.
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of its target gene [1–4]. Interestingly, immunogold labeling
analysis demonstrated that not only the protein levels of nucle-
ar p53 was increased, but also higher levels of p53 were ob-
served in mitochondria, which occurred prior to the onset of
apoptosis [1]. p53 mitochondrial translocation has been well-
recognized in the literature [5–8], and the roles of mitochon-
drial p53 are similar to that of nuclear p53, which include
maintaining mitochondrial DNA integrity and facilitating
apoptosis by forming complexes with pro/anti-apoptotic Bcl-
2 family members [16–18]. Questions remained include how
p53 is transported into mitochondria and how mitochondrial
p53 interacts with mitochondrial functions, etc. Given the fact
that p53 itself dose not contain a mitochondrial localization se-
quence, a recent study [19] suggests that ubiquitination plays
an important role in p53 mitochondrial translocation.
The present study was aimed to investigate the role of
mitochondrial permeability transition pore (mPTP) in p53
mitochondrial translocation. Mitochondrial permeability tran-
sition stands for an increase in mitochondrial membrane per-
meability, which is resulted from opening of mPTP. PTP
plays an important role in intrinsic apoptosis. Since PTP is in-
volved in mitochondrial p53-mediated apoptosis [16], we
hypothesize that inhibition of mPTP may aﬀect p53 transloca-
tion. Two mPTP blockers were used in the studies: cyclosporin
A and bongkrekic acid. Inhibition of apoptosis by blocking
mPTP with cyclosporin A has been observed in various cell
types [20].
The studies were performed in skin epidermal JB6 cells and
skin epidermal tissues, in which p53 mitochondrial transloca-
tion and distribution caused by tumor promoter (TPA) treat-
ment, have been revealed [1–4]. The results demonstrated
that by blocking mPTP using cyclosporin A or bongkrekic
acid, TPA-induced p53 mitochondrial translocation was inhib-
ited. Correspondingly, the subsequent mitochondrial dysfunc-
tion (decrease in membrane potential and Complex I activity)and apoptosis were reduced. Similar results were also seen in
skin keratinocyte 308 cells (unpublished data). The underlying
mechanism(s) of how blocking of mPTP prevents p53 translo-
cation needs to be investigated in future studies. TPA-induced
generation of mitochondrial reactive oxygen species may play
an important role since applying a potent SOD mimetic,
MnTE-2-PyP5+, is able to prevent subsequent p53 transloca-
tion [3]. Our unpublished data show that CsA inhibits TPA-in-
duced ROS generation, providing a possible mechanism.
Oxidative stress-induced apoptosis can be mediated by the
opening of mitochondrial permeability transition pore. Cyclo-
sporine A is known to directly bind to a mPTP component,
cyclophilin D, interfering the opening of mPTP. On the other
hand, mitochondrial p53 has been shown to interact with one
primary antioxidant enzyme localized in mitochondria,
MnSOD, leading to inactivation of its enzymatic activity and
propagation of oxidative stress [3], which may promote the
opening of mPTP and apoptosis. All in all, our results suggest
that mPTP may exert its role in controlling p53-mediated
apoptosis by, at least in part, preventing p53 mitochondrial
translocation.
In summary, our studies in skin epidermal JB6 cells and skin
epidermal tissues, which showed that blocking mPTP sup-
pressed p53 translocation, add a possibility that p53 transloca-
tion into mitochondria may require the opening of the mPTP.
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